SKYLINE

Phase 2, single-arm study, preceded by a safety rod-in phase, evaluating the effectiveness of the tiragolumab-atezolizumab combination and chemotherapy in triple-negative breast cancer with 2 parallel cohorts: (i) in phase neo-adjuvant (cohort A) and (ii) in 1st line metastatic (cohort B).;The objective of our study is to evaluate the effectiveness of the atezolizumab + tiragolumab + chemotherapy combination in early and metastatic triple negative breast cancer.;As the Atezolizumab + Tiragolumab + chemotherapy combination has never been tested, a safety rod-in phase is planned in each cohort in order to verify the tolerance of the combination.